In a randomized controlled trial, no cognitive benefits to adults with mild cognitive impairment or Alzheimer’s disease were observed with intranasal insulin treatment compared to placebo over a 12-month period; however, the study execution and the interpretation of results were complicated by issues with the intranasal delivery device [62]. Here, INS is linked to Alzheimer disease.